Logo
I

ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant)

169 employees

ISTA Pharmaceuticals, Inc, was a rapidly growing specialty pharmaceutical company developing, marketing and selling products in the U.S. and Puerto Rico. It was the fourth largest branded prescription eye care business in the U.S. and had an emerging allergy drug franchise. Its products treated ocular inflammation and pain, glaucoma, dry eye and ocular allergies. It had a U.S. sales force of more than 165 representatives calling on ophthalmologists, optometrists and allergists. The four key products included: • BROMDAY™ (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions • BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% for the treatment of ocular itching associated with allergic conjunctivitis • ISTALOL® (timolol maleate ophthalmic solution) 0.05% for the treatment of glaucoma • VITRASE® (hyaluronidase injection) ovine, 200 USP units/ml for use as a spreading agent In June of 2012, ISTA was acquired by Bausch + Lomb and now operates under the Pharmaceutical business of Bausch + Lomb. In July of 2013, Bausch + Lomb was acquired by Valeant.

Investor insights

Funding rounds participated in

$65M sweet spot round size

Investor type

Public Company

Basic info

Industry

Pharmaceutical Manufacturing

Sectors

Pharmaceutical Manufacturing

Date founded

2000

Funding rounds raised

Total raised

$65M

from investors over 1 rounds

I

ISTA Pharmaceuticals (Products now under Bausch + Lomb, which was acquired by Valeant) raised $65M on October 26, 2008

FAQ